BioNTech SE

333.48-19.51-5.53%Vol 2.57M1Y Perf 435.56%
Sep 24th, 2021 16:00 DELAYED
BID333.50 ASK335.70
Open350.00 Previous Close352.99
Pre-Market- After-Market-
 - -  - -%
Target Price
290.88 
Analyst Rating
Moderate Buy 2.14
Potential %
-12.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     65.78
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     74.27
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
67.59 
Earnings Rating
Market Cap80.87B 
Earnings Date
9th Nov 2021
Alpha0.21 Standard Deviation0.29
Beta-1.59 

Today's Price Range

332.40350.92

52W Range

61.27464.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-7.16%
1 Month
-11.32%
3 Months
44.98%
6 Months
250.55%
1 Year
435.56%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BNTX333.48-19.5100-5.53
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 20218.3512.9855.45
Q01 20214.315.2922.74
Q04 2020-0.571.87428.07
Q03 2020-0.46-1.03-123.91
Q02 2020-0.29-0.42-44.83
Q01 2020-0.30-0.2613.33
Q04 2019-0.19-0.29-52.63
Q03 2019-0.21-0.1623.81
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Nov 2021
Estimated EPS Next Report10.68
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.57M
Shares Outstanding242.52M
Shares Float242.52M
Trades Count52.11K
Dollar Volume132.94M
Avg. Volume3.10M
Avg. Weekly Volume2.42M
Avg. Monthly Volume3.02M
Avg. Quarterly Volume4.14M

BioNTech SE (NASDAQ: BNTX) stock closed at 333.48 per share at the end of the most recent trading day (a -5.53% change compared to the prior day closing price) with a volume of 2.60M shares and market capitalization of 80.87B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1310 people. BioNTech SE CEO is Ugur Sahin.

The one-year performance of BioNTech SE stock is 435.56%, while year-to-date (YTD) performance is 309.08%. BNTX stock has a five-year performance of %. Its 52-week range is between 61.27 and 464, which gives BNTX stock a 52-week price range ratio of 67.59%

BioNTech SE currently has a PE ratio of 19.90, a price-to-book (PB) ratio of 13.97, a price-to-sale (PS) ratio of 8.94, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 80.46%, a ROC of 126.76% and a ROE of 133.85%. The company’s profit margin is 52.41%, its EBITDA margin is 73.60%, and its revenue ttm is $9.20 Billion , which makes it $37.93 revenue per share.

Of the last four earnings reports from BioNTech SE, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $10.68 for the next earnings report. BioNTech SE’s next earnings report date is 09th Nov 2021.

The consensus rating of Wall Street analysts for BioNTech SE is Moderate Buy (2.14), with a target price of $290.88, which is -12.77% compared to the current price. The earnings rating for BioNTech SE stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioNTech SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioNTech SE has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.34, ATR14 : 22.28, CCI20 : -41.43, Chaikin Money Flow : -0.07, MACD : 0.83, Money Flow Index : 57.70, ROC : -0.82, RSI : 47.03, STOCH (14,3) : 21.02, STOCH RSI : 0.00, UO : 48.32, Williams %R : -78.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioNTech SE in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (42.86 %)
2 (28.57 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (57.14 %)
5 (71.43 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.14
Moderate Buy
2.43
Moderate Buy
1.86

BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

CEO: Ugur Sahin

Telephone: +49 613190840

Address: An der Goldgrube 12, Mainz D-55131, , DE

Number of employees: 1 310

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

TipRanks News for BNTX

Thu, 23 Sep 2021 11:50 GMT Pfizer-BioNTech Booster Dose Bags FDA Approval

- TipRanks. All rights reserved.

Tue, 21 Sep 2021 10:23 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Veru (VERU) and Syros Pharmaceuticals (SYRS)

- TipRanks. All rights reserved.

Mon, 06 Sep 2021 17:41 GMT Can Investors Buy at Modernas Current Valuation

- TipRanks. All rights reserved.

Tue, 31 Aug 2021 10:25 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Anixa Biosciences (ANIX)

- TipRanks. All rights reserved.

Thu, 26 Aug 2021 09:32 GMT BioNTechs Capabilities Questionable, Despite Vaccine Victory

- TipRanks. All rights reserved.

Tue, 24 Aug 2021 09:47 GMT Pfizer-BioNTechs COVID-19 Vaccine Bags Full FDA Approval

- TipRanks. All rights reserved.

Fri, 13 Aug 2021 12:26 GMT Analysts Conflicted on These Healthcare Names: BioNTech SE (BNTX), Humanigen (HGEN) and Ikena Oncology (IKNA)

- TipRanks. All rights reserved.

News

Stocktwits